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Abstract
Tibial muscular dystrophy (TMD) is a late onset, autosomal dominant distal myopathy that results from mutations in the two
last domains of titin. The cascade of molecular events leading from the causative Titin mutations to the preterm death of
muscle cells in TMD is largely unknown. In this study we examined the mRNA and protein changes associated with the
myopathology of TMD. To identify these components we performed gene expression profiling using muscle biopsies from
TMD patients and healthy controls. The profiling results were confirmed through quantitative real-time PCR and protein
level analysis. One of the pathways identified was activation of endoplasmic reticulum (ER) stress response. ER stress
activates the unfolded protein response (UPR) pathway. UPR activation was supported by elevation of the marker genes
HSPA5, ERN1 and the UPR specific XBP1 splice form. However, UPR activation appears to be insufficient to correct the protein
abnormalities causing its activation because degenerative TMD muscle fibres show an increase in ubiquitinated protein
inclusions. Abnormalities of VCP-associated degradation pathways are also suggested by the presence of proteolytic VCP
fragments in western blotting, and VCP’s accumulation within rimmed vacuoles in TMD muscle fibres together with p62 and
LC3B positive autophagosomes. Thus, pathways controlling turnover and degradation, including autophagy, are distorted
and lead to degeneration and loss of muscle fibres.
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Introduction
Tibial muscular dystrophy (TMD, OMIM: #600334, Udd
myopathy) is an autosomal dominant distal myopathy with a
particularly high prevalence in the Finnish population [1–3]. The
disease is caused by heterozygous mutations in the last two exons
(Mex5-6) of the Titin (TTN) gene [4]. Five other phenotypes have
been reported to be associated with C-terminal titin mutations:
recessive limb-girdle muscular dystrophy type 2J (LGMD2J) [2],
dominant hereditary myopathy with early respiratory failure [5,6],
recessive early-onset myopathy with fatal cardiomyopathy [7],
core myopathy with heart disease [8] and centronuclear myopathy
[9]. All Finnish TMD patients reported so far share the 11 bp
deletion/insertion FINmaj founder mutation [1,2], which results
in C-terminal defects in the M-line region of the sarcomeric titin
protein [2]. Several other mutations in the last two exons of TTN
have been shown to cause TMD in patients of other European
populations [4,10,11].
TMD is clinically characterised by atrophy and weakness in the
muscles of the anterior compartment of the lower leg (tibialis
anterior, extensor hallucis longus and extensor digitorum longus) [3], with
typical onset between 35–55 years [12]. Homozygous FINmaj
mutations cause the manifestation of the completely different, and
much more severe, early onset LGMD2J (OMIM: #608807)
[2,3,13]. TMD and LGMD2J patients do not have facial muscle
weakness, dysphagia or clinically manifest cardiomyopathy. TMD
muscle biopsies show myopathic–dystrophic morphology with rare
fibre necrosis and frequent rimmed vacuolated fibres in affected
muscles [3,12,14].
Titin molecules are integral to striated muscle structure and
function by forming the backbone of the continuous third filament
system of the myofibrils. The titin molecule stretches from the Z-
disc to the M-line of the sarcomere. One of titin’s core functions is
to provide muscle elasticity by returning thin and thick filaments to
their positions after contractions [15,16]. The last Ig-domain
(M10) containing the FINmaj mutation is adjacent to the
differentially spliced [17] is7 domain that contains a calpain-3
(CAPN3) binding site [13]. Immunofluorescent (IF) microscopy of
homozygous mutant muscles has revealed an absence of C-
terminal titin epitopes from at least the three last domains M9, is7
and M10 [2]. Together with the loss of M-line CAPN3 and
mislocalization of the C-terminal ligand obscurin, this suggests that
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the FINmaj mutation leads to a proteolytic cleavage of the titin C-
terminus [13,18,19].
As the downstream molecular pathology caused by the FINmaj
mutation is still largely unknown, the objective of this study was to
identify relevant changes through global expression profiling of
affected distal muscles from TMD patients. Significantly changed
pathways were identified and confirmed through quantitative real-
time PCR and protein level analysis of marker molecules.
Materials and Methods
Ethics statement
All patient biopsies were obtained with written informed
consent and according to the Helsinki declaration. The study
was approved by the institutional review board of Helsinki
University Hospital.
Muscle biopsies
All patients were diagnosed based on DNA mutation testing.
Control and patient biopsies were obtained from the distal muscles
of male and female patients in a range of ages (37–92; Table 1).
RNA preparation
RNA was extracted from frozen muscles samples using
RNAeasy mini kit’s (Qiagen, USA) recommended protocol. The
RNA quality was assessed using a 2100 Bioanalyzer and the
Eukaryote total RNA Nano series II program (Agilent technolo-
gies, USA).
Microarray analysis
3 mg of total RNA was used to generate double stranded cDNA.
The cRNA was generated using either one- or two-cycle eukaryote
target labelling along with controls supplied with the kit
(Affymetrix, USA). The samples were biotin labelled and the
cRNA randomly fragmented before hybridisation to Affymetrix
U133plus2 microarrays following the manufacturer’s instructions.
The microarray chips were washed and stained using Affymetrix
Fluidics Station and scanned using a GeneChip Scanner 3000.
Expression values were determined using Affymetrix Micro-
array Suite 5.0 and GeneSpring GX version 11.0 (Agilent
Technologies, USA) was used for pre-processing the data using
the MAS5 algorithm. All probe sets with absent flags were
removed from the data. The data was baseline transformed to the
median of all samples. Differentially expressed genes were detected
using an unpaired t-test with unequal variance (Welch correction).
P-values were corrected using a Benjamini-Hochberg adjustment
for multiple testing. Probe sets having a P,0.05 and at least a two-
fold change were considered to be differentially expressed. The
microarray data is available from the GEO website (http://www.
ncbi.nlm.nih.gov/geo/) with accession number GSE42806.
Table 1. Summary of patient and control muscle biopsies.
Expression array qPCR WB/IF/IHC Biopsy Diagnosis Sex Age at biopsy Pathology
T1 rT1 EHL TMD M 53 Rimmed vacuoles
T2 GL TMD M 62 No rimmed vacuoles
T3 TA TMD M 48 Rimmed vacuoles
T4 rT2 TMD 5 EHL TMD M 65 Rimmed vacuoles
T5 SOL TMD M 52 Rimmed vacuoles
T6 TP TMD M 52 No major pathology
T7 TA TMD M 52 Rimmed vacuoles
rT3 EHL TMD M 92 Not known
rT4 TA TMD M 73 Rimmed vacuoles
rT5 TA TMD M 78 Rimmed vacuoles
TMD 1 EHL TMD M 62 Rimmed vacuoles
TMD 2 TA TMD M 55 Rimmed vacuoles
TMD 3 GM TMD M 67 Rimmed vacuoles
TMD 4 EDL TMD F 50–55 Rimmed vacuoles
TMD 6 TA TMD M 44 Rimmed vacuoles
C1 rC1 TP Control M 76 Normal
C2 EHL Control M 76 Normal
C3 rC2 TA Control M 80 Normal
C4 rC3 EHL Control M 80 Normal
C5 SOL Control M 76 Normal
Ctrl 1 TA Control M 37 Normal
Ctrl 2 TA Control F 48 Normal
Ctrl 3 THP Control F 91 Normal
Tibialis anterior (TA), tibialis posterior (TP), gastrocnemius lateralis (GL), gastrocnemius medialis (GM), soleus (SOL), extensor hallucis longus (EHL), extensor digitorum longus
(EDL), thigh posterior (THP), immunofluorescence microscopy (IF), western blotting (WB) and immunohistochemistry (IHC). The expression array controls (C1, C2 & C5)
and (C3 & C4) were collected from amputation material from the distal lower limb muscles of two individuals.
doi:10.1371/journal.pone.0090819.t001
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Pathway Analysis
Pathway analysis was done using Ingenuity Pathway Analysis
software (www.ingenuity.com). The significance of each canonical
pathway having more affected genes than expected by chance in
the data set was determined by the Fisher’s exact t-test (P,0.05).
Quantitative real-time PCR
RNAwas extracted from tissue biopsies using a Trizol (Invitrogen,
USA) based protocol according to the manufacturer’s suggestions.
1 mg of total RNA was reverse-transcribed to cDNA using
SuperScript II Reverse Transcriptase (Invitrogen, USA) following
the manufacturer’s protocol. Quantification of the cDNA was
performed using TaqMan based quantitative real-time PCR. The
primers and probes used were the spliced form of XBP1
(Hs00231936_m1), HSPA5 (Hs00607129_gH), ERN1 (Hs009800
93_m1), JUN (Hs99999141_s1), HSPB1 (Hs03044127_g1) and
GAPDH (4333764F). 10 ml TaqMan master mix (Applied Biosys-
tems, USA), 0.5 ml 1:10 diluted cDNA and 2 ml of primer and probe
set were used in a 20 ml total reaction volume. Amplification and
detection were performed using the ABI 7500 system (Applied
Biosystems, USA). The PCR thermal conditions were 50uC for
2 min, 95uC for 10 s and 60uC for 1 min. Each sample was
performed in triplicate and the expression was normalised to GAPDH
using standard curves for each gene on the same plate.
Statistical analysis
Statistical significance of the quantitative real-time PCR and
western blotting results were calculated using an unpaired t-test
(P,0.05).
Western blotting
Muscle biopsies were homogenized with 19 volumes of sample
buffer containing 4 M urea and 4% SDS at 100uC for 5 min.
Samples were resolved using 12% SDS-PAGE gels with 4%
stacking gels and transferred to PVDF membranes (Bio-Rad
Laboratories, USA). Membranes were blocked in TBST 5% milk
for 1 h at +4uC. Primary and secondary HPR-conjugated
antibodies were incubated at +4uC for 1 h each, followed by 66
TBST (5 min) washes. Antibodies were detected using the
SuperSignal West Femto ECL substrate (Pierce, Thermo Scien-
tific, USA) and captured using photographic film. Protein loading
was assessed by staining of the post-blotting gel using Bio-Safe
Coomassie Stain (Bio-Rad Laboratories, USA). Antibodies used
are listed in Table S1. Quantitative analysis of western blotting
bands was performed using ImageJ version 1.46f (http://rsb.info.
nih.gov/ij/).
Immunohistochemistry and immunofluorescence
Muscle biopsies were snap frozen in liquid nitrogen cooled
isopentane to make 6 mm cryosections on SuperFrost (Kindler
GmbH, Germany). The sections were fixed in 4% PFA for
10 min, permeabilized in 0.2% Triton X-100 for 10 min, and
blocked in 5% BSA for 30 min at room temperature. The DAB
immunohistochemistry (IHC) (Universal DAB detection, Ventana,
USA) was performed using the BenchMark automated immunos-
tainer following manufacturer’s instructions. LAMP2 IHC signal
was enhanced using an amplification kit (cat. 760-080, Ventana,
USA). Herovici staining (a modified van Gieson stain) on frozen
muscle sections was used for identification of the rimmed vacuoles.
The immunofluorescence microscopy was performed as described
earlier [20]. Antibodies are listed in Table S1.
Results
Expression profiling and pathway analysis
The expression profiles of seven TMD and five control biopsy
samples were hierarchically clustered (Fig. 1). Significantly
(P,0.05) changed probe sets in the TMD samples representing
all differentially expressed transcripts are given in Table S2.
Ingenuity Pathway Analysis (IPA) showed that endoplasmic
reticulum (ER) stress response-, NRF2 mediated oxidative stress-
, PTEN-, integrin- and EIF2- signalling pathways were among the
most clearly affected pathways in TMD (Fig. 2A, 2B & 2C). There
were also a range of pathway changes that have been identified in
other myopathies with rimmed vacuoles such as; SAPK/JNK
apoptosis- [21], p70S6K- [22,23], protein ubiquitination- [23,24]
and mitochondrial dysfunction- [24,25] signalling (Fig. 2B, 2C, &
2D).
Verification of selected expression changes by
quantitative real-time PCR
We chose to investigate ER stress response in TMD muscle
since this pathway had the highest fraction of genes with
significantly changed expression compared to controls. Unfolded
protein response (UPR) is the main mechanism used to alleviate
the effects of ER stress. HSPB1 proteins are involved in the ER
stress response [26], whilst HSPA5 (BIP) [27], ERN1 (IRE1) [28]
and the spliced form of XBP1 [29] are involved in the UPR
pathway. Significant (P,0.05) up-regulation was observed in the
expression of HSPA5 (Fig. 3A), HSPB1 (Fig. 3B), ERN1 (Fig. 3C)
and the previously described UPR specific XBP1 splice isoform
(Fig. 3D) in TMD samples versus controls.
The SAPK/JNK apoptotic signalling pathway was significantly
(P,0.05) changed in the TMD samples compared to controls in
IPA analysis. We analysed JUN (CJUN) expression by quantitative
real-time PCR, as it is a final stage component of this pathway,
and found significantly elevated expression levels of JUN in TMD
samples (Fig. 3E).
Figure 1. Hierarchal clustering of TMD and control expression
profiles. Clustering of differentially expressed probes using centroid
linkage and euclidean similarity in GeneSpring GX v11.0. The expression
profiles of TMD (T1–T5) and controls (C1–C5) are represented as a
heatmap (blue = low expression, red = high expression). A list of
significantly changed probes is in Table S2.
doi:10.1371/journal.pone.0090819.g001
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Analyses of UPR pathway components on the protein
level
Numerous rimmed vacuoles were identified in TMD biopsy
sections by Herovici staining (Fig. 4A). We observed abnormalities
in the ubiquitin-proteasome system (UPS) such as cytoplasmic
ubiquitin containing inclusions (Fig. 4B) in the rimmed vacuolated
fibres in IHC. We also observed the presence of HSPA5 granular
cytoplasmic dots in non-vacuolated fibres by IF microscopy in
TMD muscle biopsies (Fig. 5A), which were not observed in
controls (Fig. 5B). This was in line with the up-regulation of
HSPA5 we found by quantitative real-time PCR analysis (Fig. 3A).
By western blotting HSPA5 levels were increased in two out of five
biopsies (Fig. 6A).
Analysis of the ERAD pathway at the protein level
Abnormal or misfolded proteins within the ER are directed into
the ER-associated protein degradation (ERAD) pathway. VCP is
involved in proteasome-autophagy crosstalk [30,31] and is a core
component of the ERAD pathway [32]. In all 5 TMD biopsies
tested by IHC, we observed a variable frequency of VCP-positive
material connected with rimmed vacuoles (Fig. 4D). Abnormal
VCP immunoreactivity was present as bodies in over half of the
rimmed vacuoles. VCP labelling was also found in a subset of
Figure 2. Ingenuity Pathway Analysis of TMD expression profiles. (A) Cell stress pathways affected in TMD also showing the ratio of
significantly changed genes versus all genes in the given pathway (oxidative stress response; abbreviated to OSR). (B) Significantly altered cell stress
and toxicity pathways, (C) apoptosis pathways, and (D) selected other pathways. The dotted line indicates the statistical significance threshold from a
Fisher’s exact t-test (P,0.05).
doi:10.1371/journal.pone.0090819.g002
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nuclei in control and TMD sections but did not differ between
disease and controls samples. Western blotting (Fig. 6B) showed an
increase in full length VCP in two TMD samples and an extra
band (70 kDa) below the full length VCP in a third sample.
Intriguingly, an extra 25-kDa band was observed in three out of
five TMD biopsies and not in the controls. These bands were
identified as D179-cleaved VCP by staining with a specific
antiserum [33] (Fig. 6C). However, by quantification the increased
levels of the 25-kDa VCP cleavage product in TMD did not reach
statistical significance (P=0.077).
Analyses of autophagy pathway components on the
protein level
If a protein abnormality cannot be correctly handled and
processed through UPR activation using the UPS for degradation,
the proteins may be redirected to the autophagic pathway and
degraded in the lysosomal system. We observed strong immuno-
reactivity of the autophagosome marker LC3B in the rimmed
vacuoles and in the cytoplasm of very atrophic fibres (Fig. 4C).
Accumulation of p62 and the autophagosome marker LC3B have
been used to indicate abnormalities in the autophagic degradation
pathways [34–36]. We observed p62 immunoreactivity in rimmed
Figure 3. Quantitative real-time PCR analysis of key components of selected pathways. Expression of (A) HSPA5, (B) HSPB1, (C) ERN1, (D)
spliced (s) XBP1, and (E) JUN normalised to GAPDH by quantitative real-time PCR from muscle biopsy total RNA (arbitrary units). *Indicates statistical
significance in an unpaired t-test (P,0.05) comparison to the control group. The average and standard deviation of five TMD and three control
biopsies each performed in triplicate are shown.
doi:10.1371/journal.pone.0090819.g003
Expression Profiling in Tibial Muscular Dystrophy
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e90819
vacuoles and granular immunoreactive dots in many atrophic
fibres (Fig. 4E). There was no overall increase in immunoreactivity
in the lysosomal marker LAMP2 in TMD fibres or within the
rimmed vacuoles (Fig. 4F & 5C) when compared to controls
(Fig. 4L & 5D).
Discussion
The expression profiling results showed that the samples
clustered according to the disease diagnosis as expected. IPA
showed that there were differences in distinct molecular pathways
between the TMD and the control samples. We were able to
confirm selected changes in the studied pathways through
quantitative real-time PCR and protein level analysis in the
TMD samples.
Pathway analysis indicated a change in the unfolded protein
response (UPR) pathway in the TMD samples. This was also
suggested by the induction of ER stress response gene HSPB1 and
UPR genes HSPA5, ERN1 and the splice form of XBP1 in
quantitative real-time PCR. The HSPA5 protein also showed
restricted areas of increased expression in IF microscopy. Many of
the proteins studied showed large variations between samples, and
these differences may be due to the patient’s biopsy site, disease
severity or age at muscle biopsy. UPR activation has been reported
in other rimmed vacuolar myopathies with abnormal UPS or
lysosomal degradation pathways [37–40], and mildly in a mouse
model of desminopathy [41]. This suggests UPR may act as a
common protective mechanism during myopathic protein based
stress. FINmaj mutated titin appears to cause the activation of
UPR and lead to accumulation of ubiquitinated proteins. The
increase of ubiquitinated protein components in TMD muscle is
unlikely to be related to CAPN3 dysfunction. A secondary CAPN3
defect is present in homozygous LGMD2J, but in heterozygous
TMD patients CAPN3 expression, although variable, is typically
within the normal range [13].
Figure 4. Histology and immunohistochemical analysis of TMD muscle biopsies. (A) Herovici histology staining of TMD muscle sections
showing rimmed vacuolar regions within the fibres. (B) Immunohistochemical (IHC) analysis of TMD muscle sections stained for ubiquitin showing
localised cytoplasmic ubiquitin containing inclusions in atrophic and rimmed vacuolated fibres and immunoreactivity at the edge of rimmed
vacuoles. (C) Autophagosome marker LC3B staining showed strong immunoreactivity within the rimmed vacuolar regions. (D) VCP staining showed
immunoreactivity in bodies within a large subset of rimmed vacuoles. (E) p62 staining showed immunoreactivity in rimmed vacuoles and granular
immunoreactive dots (shown by an arrow) in an atrophic fibre. (F) Lysosomal protein LAMP2 staining showed no overall increase in rimmed
vacuolated fibres. Two separate TMD fibres (A–C and D–F) with rimmed vacuoles in serial sections are shown. Controls of (G) Herovici staining, (H)
ubiquitin, (I) LC3B, (J) VCP, (K) p62 and (L) LAMP2 IHC are included for comparison. Sections are from samples TMD 6 and Ctrl 3 in Table 1. Scale bar
50 mm.
doi:10.1371/journal.pone.0090819.g004
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Excess of misfolded proteins in the ER may also activate the
ERAD system [42]. A key component of the ERAD pathway is
VCP which, among others, retro-translocates unfolded proteins
from the ER into the cytosol for degradation by the UPS [43].
Primary mutations in VCP cause a muscle disease with rimmed
vacuolar pathology [44,45]. VCP has also been reported to
regulate ubiquitin-containing autophagosome maturation during
myopathic proteomic stress [30,31], and may therefore be
involved in autophagosomal activation in TMD muscle. VCP
accumulates inside of rimmed vacuoles suggesting that it may have
a role in TMD myopathology with similarities to other neurode-
generative proteinopathies such as VCP-mutated myopathy
[44,45]. Western blotting showed an increase in two out of five
biopsies and an extra band beneath the full length form in a third
biopsy. In addition, we observed unconventional anti-VCP
positive bands of approx. 25 kDa in size in 3 of 5 TMD samples.
These ,25 kDa bands were subsequently confirmed to be VCP
cleavage products by specific antiserum [33]. The expression of
these VCP cleavage fragments has been reported to impair
degradation by the UPS system in neuroblastoma cells [33], but
further studies are required before this pathway can be linked to
the pathomechanism of TMD.
The p62 protein acts as an auxiliary autophagy factor by
directly binding ubiquitinated proteins and LC3, to facilitate their
degradation by autophagy [35]. However, p62 also shuttles
ubiquitinated proteins to the proteasome for degradation [46]
and has been found in protein aggregates in other neuromuscular
and neurodegenerative disorders [47–49]. The accumulation of
LC3B positive autophagosome material and p62 within the
rimmed vacuolated regions of the degenerative muscle fibres
suggests massive activation of compensatory autophagy mecha-
nisms in TMD. Cytoplasmic increase of LAMP2 has been
reported in atrophic fibres in other rimmed vacuolar myopathies
[50]. However, there was no consistent increase of mature
lysosomes based on LAMP2 staining’s in atrophic rimmed
vacuolated TMD muscle fibres. Apparently the increased induc-
tion of autophagy is not paralleled by increased autophagic flux
and further processing, which may cause the observed massive
increase of LC3B compartments.
JUN, a final stage component of SAPK/JNK apoptosis
signalling pathway was significantly increased in quantitative
Figure 5. Immunofluorescent microscopy of TMD and control biopsies. (A) HSPA5 staining showed the presence of cytoplasmic granular
dots in non-vacuolated TMD muscle fibres. The LC3B channel showed the area has no vacuolated fibres and no autofluorescent material present. (B)
A control of HSPA5/LC3B double staining was included for comparison. (C) LAMP2 and LC3B double staining of a TMD muscle fibre showed a
representative rimmed vacuole with massive accumulation of LC3B inside and negligible signal from LAMP2 around the edge of the fibre. The top
right corner of the LC3B image showed a rimmed vacuole in bright field. (D) A control of LAMP2/LC3B double staining was included for comparison.
All images are nuclear counterstained with DAPI (blue signal). Sections are from samples TMD 6 and Ctrl 3 in Table 1. Scale bar 50 mm.
doi:10.1371/journal.pone.0090819.g005
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real-time PCR analysis. In distal myopathy with rimmed vacuoles
(DMRV) JUN has been shown to be increased in vacuolated fibres
[21]. Nevertheless, whether increased apoptosis leads to a loss of
muscle fibres in TMD remains unsettled. A previous study [13]
has indicated that apoptosis may not be consistently increased in
TMD muscle, although apoptosis is increased in the homozygotic
LGMD2J [13] muscle. However, the muscle pathology of
LGMD2J is different to TMD and does not show rimmed
vacuolar changes.
This study, based on expression profiling and molecular
pathology, has identified changes in several subcellular molecular
pathways that are apparently involved in the TMD pathomech-
anism. These include activation of UPR accompanied by
increased amounts of ubiquitinated proteins and altered autoph-
agic degradation leading to atrophic and rimmed vacuolated
degenerated fibres. Apparently a variety of entries, i.e. different
mutant proteins, can result in similar changes in catabolic
pathways that control protein turnover. The changes identified
in this study are downstream secondary effects of the primary
FINmaj mutation in titin. The exact molecular mechanisms that
trigger UPR, ERAD and autophagic dysregulation as well as the
other abnormally regulated pathways identified in this study need
further characterization in order to identify steps that could be
therapeutically useful.
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